NOK 4.6
(-12.21%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -37.78 Million NOK | -42.62% |
2022 | -30.28 Million NOK | 23.73% |
2021 | -37.94 Million NOK | -99.38% |
2020 | -20.88 Million NOK | -716.16% |
2019 | -2.32 Million NOK | -267.7% |
2018 | -663.82 Thousand NOK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -11.36 Million NOK | 0.0% |
2024 Q1 | -11.36 Million NOK | 7.06% |
2023 Q4 | -12.23 Million NOK | 0.0% |
2023 FY | - NOK | -42.62% |
2023 Q1 | 1.2 Million NOK | 114.48% |
2023 Q3 | -12.23 Million NOK | 0.0% |
2023 Q2 | - NOK | -100.0% |
2022 Q4 | -8.29 Million NOK | 0.0% |
2022 FY | - NOK | 23.73% |
2021 FY | - NOK | -99.38% |
2020 FY | - NOK | -716.16% |
2019 FY | - NOK | -267.7% |
2018 FY | - NOK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Aqua Bio Technology ASA | -16.56 Million NOK | -128.065% |
ArcticZymes Technologies ASA | 31.64 Million NOK | 219.405% |
BerGenBio ASA | -191.8 Million NOK | 80.3% |
Hofseth BioCare ASA | -70.6 Million NOK | 46.482% |
PCI Biotech Holding ASA | -22.22 Million NOK | -70.032% |
Thor Medical ASA | -6.82 Million NOK | -453.295% |
Ultimovacs ASA | -214.85 Million NOK | 82.414% |